By Frank Prenesti
Date: Tuesday 30 Jan 2024
LONDON (ShareCast) - (Sharecast News) - Pharmaceutical giant Pfizer reported better-than-expected quarterly earnings on Tuesday, driven by its cost-cutting programme aimed at an eventual return to profitability.
The company reported a fourth-quarter net loss of $3.37bn, compared with net income of $5bn a year-earlier. Revenues fell 41% to $14.24bn - below consensus estimates of $14.37bn.
Pfizer said the US government returned fewer courses of its Covid Paxlovid drug than expected, leading to a $3.5bn revenue reversal for the return of about 6.5 million doses compared with a prior forecast of a $4.2bn based on the return of around 7.9 million courses at the end of 2023.
Revenues from Covid products, antiviral treatment Paxlovid and Covid vaccine Comirnaty, came in at $12.5bn for 2023. Pfizer makes the Comirnaty vaccine with German partner BioNTech.
The company has set a $4bn cost-cutting target and has set its sights on growing earnings through its cancer treatments.
Reporting by Frank Prenesti for Sharecast.com
Email this article to a friend
or share it with one of these popular networks:
Currency | US Dollars |
Share Price | $ 27.42 |
Change Today | $ -0.57 |
% Change | -2.04 % |
52 Week High | $37.51 |
52 Week Low | $25.26 |
Volume | 29,843,734 |
Shares Issued | 5,646m |
Market Cap | $154,813m |
RiskGrade | 102 |
Strong Buy | 3 |
Buy | 6 |
Neutral | 15 |
Sell | 0 |
Strong Sell | 0 |
Total | 24 |
Time | Volume / Share Price |
16:00 | 4,047,779 @ $27.42 |
15:59 | 269 @ $27.42 |
15:59 | 300 @ $27.42 |
15:59 | 100 @ $27.42 |
15:59 | 100 @ $27.42 |
You are here: research